Safety and Efficacy of Medical Cannabis Oil for Behavioral and Psychological Symptoms of Dementia: An-Open Label, Add-On, Pilot Study.

Authors :: Shelef A
Barak Y
Berger U
Paleacu D
Tadger S
Plopsky I
Baruch Y
Source :: Journal of Alzheimer's disease : JAD [J Alzheimers Dis] 2016; Vol. 51 (1), pp. 15-9.
Publication Year :: 2016
Abstract: Background: Tetrahydrocannabinol (THC) is a potential treatment for Alzheimer's disease (AD).<br />Objective: To measure efficacy and safety of medical cannabis oil (MCO) containing THC as an add-on to pharmacotherapy, in relieving behavioral and psychological symptoms of dementia (BPSD).<br />Methods: Eleven AD patients were recruited to an open label, 4 weeks, prospective trial.<br />Results: Ten patients completed the trial. Significant reduction in CGI severity score (6.5 to 5.7; p < 0.01) and NPI score were recorded (44.4 to 12.8; p < 0.01). NPI domains of significant decrease were: Delusions, agitation/aggression, irritability, apathy, sleep and caregiver distress.<br />Conclusion: Adding MCO to AD patients' pharmacotherapy is safe and a promising treatment option.

Subjects :: Aged
Aged, 80 and over
Antipsychotic Agents therapeutic use
Behavioral Symptoms etiology
Cognition Disorders etiology
Dementia complications
Female
Humans
Male
Neuropsychological Tests
Outcome Assessment, Health Care
Physical Examination
Pilot Projects
Prospective Studies
Psychiatric Status Rating Scales
Behavioral Symptoms drug therapy
Cognition Disorders drug therapy
Medical Marijuana therapeutic use

Full Text Access

Tools